Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure

Clinical Transplantation

Volumn 19, Issue 5, 2005, Pages 573-580

  Waid, Thomas ^a   Alfrey, Edward ^b   Mulloy, Laura C ^c   Shihab, Faud S ^d   Conti, David ^e   Freeman, Richard ^f   de Mattos, Angelo M ^g   Jensik, Stephen C ^h   Jordan, Stanley ⁱ   Francos, George C ^j   Van Buren, David ^k   Chan, Larry ^l   Steiner, Robert W ^m   Basadonna, Giacomo ⁿ   Brinker, Karl ^o   Steinberg, Steven ^p   Matas, Arthur J ^q   King, Anne L ^r   Kasiske, Bertram L ^s   Cohen, David J ^t   Surer, David ^t   Inokuchi, Sharon ^u   Pirsch, John D ^v   Bromberg, Jonathan S ^w   Weir, Matthew R ^x   Greenstein, Stuart M ^y   Tomlanovich, Stephen J ^z   Mendez, Robert ^aa   Kahana, Lawrence ^ab   Henning, Alice K ^ac   First, M Roy ^ad   Fitzsimmons, William E ^ad   Salm, Kim ^ad   Tolzman, Diane ^ad   more..

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^k VANDERBILT UNIVERSITY   (United States)

^l UNIVERSITY OF COLORADO   (United States)

^m UCSD MEDICAL CENTER   (United States)

ⁿ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o Dallas Transplant Institute   (United States)

^p SHARP MEMORIAL HOSPITAL   (United States)

^q UNIVERSITY OF MINNESOTA   (United States)

^r VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s HENNEPIN COUNTY MEDICAL CENTER   (United States)

^t NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^u CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^v UNIVERSITY OF WISCONSIN MADISON   (United States)

^w MOUNT SINAI MEDICAL CENTER   (United States)

^x UNIVERSITY OF MARYLAND   (United States)

^y MONTEFIORE MEDICAL CENTER   (United States)

^z UNIVERSITY OF CALIFORNIA   (United States)

^aa St Vincent/NIT   (United States)

^ab TAMPA GENERAL HOSPITAL   (United States)

^ac EMMES CORPORATION   (United States)

^ad ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

more..

Author keywords

Cyclosporine; Graft rejection; Renal transplantation; Tacrolimus

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CORTICOSTEROID; CREATININE; CYCLOSPORIN; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TRIACYLGLYCEROL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; INCIDENCE; INFECTION; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT;

BIOPSY; CREATININE; CYCLOSPORINE; DELAYED GRAFT FUNCTION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 25144437554     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00389.x     Document Type: Review

References (29)

1. Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000: 343: 1078.
2. Hariharan S, Johnson CP, Bresnahan BA et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000: 342: 605.
3. Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002: 346: 580.
4. Hariharan S, McBride MA, Cherikh WS et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002: 62: 311.
5. Odland MD, Kasiske BL. Kidneys from female donors are at increased risk for chronic allograft rejection. Transplant Proc 1993: 25: 912.
6. Butkus DE, Meyderech EF, Raju SS. Racial differences in the survival of cadaveric renal allografts. Overriding effects of HLA matching and socioeconomic factors. N Engl J Med 1992: 327: 840.
7. McLaren AJ, Fuggle SV, Welsh KI et al. Chronic allograft failure in human renal transplantation: a multivariate risk factor analysis. Ann Surg 2000: 232: 98.
8. Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994: 57: 857.
9. Peschke B, Scheuermann EH, Geiger H et al. Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients. Clin Nephrol 1999: 51: 290.
10. Almond PS, Matas A, Gillingham K et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993: 55: 752.
11. Wissing KM, Abramowicz D, Broeders N, Vereerstraeten P. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 2000: 70: 464.
12. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001: 7: 384.
13. Burke JF Jr, Pirsch JD, Ramos EL et al. Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 1994: 331: 358.
14. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000: 11: 1910.
15. Vincenti F, Jensik SC, Filo RS et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002: 73: 775.
16. Solez K, Benediktsson H, Cavallo T et al. Report of the Third Banff Conference on Allograft Pathology (July 20-24, 1995) on classification and lesion scoring in renal allograft pathology. Transplant Proc 1996: 28: 441.
17. Racusen LC, Solez K, Colvin RB et al. The Banff 97 classification of renal allograft pathology. Kidney Int 1999: 55: 713.
18. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975: 31: 103.
19. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002: 25(Suppl. 1): S5.
20. Klein IH, Abrahams A, van Ede T et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002: 73: 732.
21. Ahsan N, Johnson C, Gonwa T et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 2001: 72: 245.
22. Mayer AD, for the European Tacrolimus Multicentre Renal Study Group. Chronic rejection and graft half-life: five-year follow-up of the European Tacrolimus Multicenter Renal Study. Transplant Proc 2002: 34: 1491.
23. Johnson RW, Kreis H, Oberbauer R et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001: 72: 777.
24. Margreiter R. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002: 359: 741.
25. Bostom AD, Brown RS Jr, Chavers BM et al. Prevention of post-transplant cardiovascular disease - report and recommendations of an ad hoc group. Am J Transplant 2002: 2: 491.
26. Pirsch JD, Miller J, Deierhoi MH et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997: 63: 977.
27. First MR, Gerber DA, Hariharan S et al. Post-transplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation 2002: 73: 379.
28. University Renal Research and Education Association; United Network for Organ Sharing. 2002 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1992-2001 [Internet]. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Office of Special Programs, Division of Transplantation, 2003 [modified 2003 Feb 18; cited 2003 June 26]. Available from: http://www.ustransplant.org/annual.html.
29. Cosio FG, Pelletier RP, Falkenhain ME et al. Impact of acute rejection and early allograft function on renal allograft survival. Transplantation 1997: 63: 1611.